How to continue Strattera after moving to Texas

If you’ve been wondering whether you can access ADHD treatment through a screen instead of a traditional doctor’s office, you’re not alone. Millions of Americans are now exploring telehealth for mental health care—including ADHD management. The short answer? Yes, you can get ADHD non-stimulant medications like Strattera (atomoxetine) prescribed via telehealth in most cases across all 50 states. Unlike stimulant medications such as Adderall or Vyvanse, non-stimulants aren’t classified as controlled substances by the DEA, which means they face fewer regulatory hurdles for remote prescribing.

But the details matter—especially as federal telehealth rules evolve and state laws vary. Whether you’re seeking treatment for the first time or looking for a more convenient way to manage your ADHD, understanding how telehealth prescribing works can help you access safe, effective care. In this guide, we’ll walk through everything you need to know: how federal and state regulations affect your options, what to expect from a telehealth ADHD evaluation, and how to choose a reputable provider.

Understanding ADHD Non-Stimulant Medications

Before diving into telehealth specifics, it helps to understand what non-stimulant ADHD medications are and how they differ from stimulants.

What Are Non-Stimulant ADHD Medications?

Non-stimulant medications treat ADHD through different mechanisms than stimulants like Adderall or Ritalin. The most commonly prescribed non-stimulant is Strattera (atomoxetine), which works by selectively inhibiting the reuptake of norepinephrine—a brain chemical involved in attention and impulse control. Unlike stimulants that work within hours, Strattera typically requires 4-6 weeks to reach full effectiveness.

Other non-stimulant options include:

• Intuniv (guanfacine)
• Kapvay (clonidine)
• Qelbree (viloxazine)

These medications aren’t controlled substances, meaning they carry no DEA scheduling classification and have no potential for abuse or dependency.

Why Choose a Non-Stimulant?

Your healthcare provider might recommend a non-stimulant medication if you:

• Have a history of substance use concerns
• Experience significant side effects from stimulants (like anxiety, sleep issues, or appetite suppression)
• Have certain cardiovascular conditions that make stimulants risky
• Prefer a medication without controlled substance restrictions
• Need 24-hour symptom coverage (Strattera provides steady effects throughout the day)

While stimulants remain the first-line treatment for many ADHD patients due to their rapid effectiveness, non-stimulants offer a valuable alternative—especially for those who can’t tolerate stimulants or where there’s concern about misuse.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Federal Telehealth Rules: What You Need to Know

The landscape of telehealth prescribing has changed dramatically since 2020, particularly for mental health conditions like ADHD.

Current DEA Regulations (As of December 2025)

Here’s the crucial distinction: Non-stimulant ADHD medications like Strattera have never been restricted for telehealth prescribing at the federal level. Because they’re not controlled substances, they’re exempt from the Ryan Haight Act’s in-person examination requirement that typically applies to controlled medications.

For context, the Ryan Haight Act (passed in 2008) normally requires patients to have at least one in-person medical evaluation before a provider can prescribe controlled substances online. However, during the COVID-19 pandemic, the DEA issued temporary waivers allowing providers to prescribe Schedule II-V controlled substances (including stimulant ADHD medications) via telehealth without an initial in-person visit.

Current status: The DEA has extended these COVID-era telehealth flexibilities through December 31, 2025. This means providers can currently prescribe both stimulant and non-stimulant ADHD medications via telehealth. However, a fourth extension for 2026 is anticipated but not yet finalized—meaning the rules could potentially change after the current extension expires.

The important takeaway: If you’re seeking non-stimulant ADHD treatment, federal law poses no special barriers to telehealth prescribing, regardless of what happens with the DEA’s temporary extensions for controlled substances.

What This Means for Patients

A licensed healthcare provider can:

• Conduct your entire ADHD evaluation via secure video visit
• Diagnose ADHD based on telehealth assessment (following DSM-5 criteria)
• Prescribe Strattera or other non-stimulant medications electronically to your pharmacy
• Provide ongoing monitoring and medication management through follow-up telehealth appointments

No in-person visit is legally required at the federal level for non-stimulant prescriptions, though your provider may recommend one for clinical reasons in certain situations.

State-by-State Considerations

While federal law sets the baseline, individual states can impose additional requirements for telehealth practice. The good news: No state completely prohibits telehealth treatment for ADHD. However, some states have specific rules worth knowing about.

States With Standard Telehealth Access

Most states, including California, Illinois, Pennsylvania, and Georgia, allow telehealth ADHD evaluations and non-stimulant prescribing without special restrictions. Providers must be licensed in your state and follow standard medical practices, but there are no mandatory in-person visit requirements for non-controlled medications.

States With Notable Requirements

New York: In May 2025, New York implemented strict rules requiring an in-person evaluation before prescribing any controlled substance via telehealth. However, this doesn’t affect non-stimulant medications like Strattera—those can still be prescribed after a telehealth-only evaluation.

Alabama: Requires an in-person visit within 12 months for ongoing telehealth treatment in most cases. There’s an important exception: mental health services are exempt from this rule. Since ADHD is a mental health condition, psychiatric telehealth care (including non-stimulant prescribing) generally doesn’t trigger Alabama’s annual in-person requirement.

Florida: Generally prohibits telehealth prescribing of Schedule II stimulants—unless it’s for a psychiatric condition. Since ADHD qualifies as a psychiatric disorder, both stimulants and non-stimulants can be prescribed via telehealth in Florida. For non-controlled Strattera specifically, there are no special state restrictions.

Texas: Very telehealth-friendly for mental health care. Texas allows telemedicine for behavioral health conditions without requiring in-person visits for ADHD treatment. However, there are limitations on which providers can prescribe certain medications (see the provider credentials section below).

New Hampshire: Recently updated its law in August 2025 to remove prior in-person requirements, now only requiring at least an annual follow-up evaluation (which can be conducted via telehealth) for controlled substance prescribing. This makes starting ADHD treatment via telehealth easier than before.

The bottom line: If you’re working with a reputable telehealth platform, they’ll ensure compliance with your state’s specific requirements. At Klarity Health, for example, we match patients with providers licensed in their state who understand all applicable regulations.

What to Expect From a Telehealth ADHD Evaluation

Getting diagnosed and treated for ADHD via telehealth isn’t a shortcut—it’s comprehensive care delivered remotely. Here’s what a legitimate evaluation looks like.

The Initial Assessment Process

A proper ADHD telehealth evaluation mirrors the thoroughness of an in-person visit:

1. Detailed Medical HistoryYour provider will ask about:

• Current symptoms and how they affect work, school, and relationships
• Childhood behavior and academic performance (ADHD symptoms must have been present before age 12)
• Family history of ADHD or other mental health conditions
• Previous treatments or medications you’ve tried
• Other medical conditions and current medications
• Substance use history

2. Symptom EvaluationExpect to complete standardized ADHD rating scales like:

• Adult ADHD Self-Report Scale (ASRS)
• Conners Adult ADHD Rating Scale
• Brown Attention-Deficit Disorder Scale

These validated questionnaires help clinicians assess symptom severity across different domains: inattention, hyperactivity, impulsivity, and functional impairment.

3. Differential DiagnosisA thorough provider will rule out other conditions that can mimic ADHD symptoms, such as:

• Anxiety disorders
• Depression
• Sleep disorders
• Thyroid problems
• Medication side effects

This is why providers ask detailed questions about mood, sleep, stress levels, and life circumstances—they need the complete picture.

4. Collateral InformationFor a more accurate diagnosis, providers may request:

• Old report cards or school records (especially helpful for adult diagnoses)
• Input from family members or partners who can describe your symptoms
• Records from previous healthcare providers

The Video Consultation

Your telehealth appointment will typically last 45-60 minutes for an initial evaluation. During this video visit, your provider will:

• Review your questionnaire responses
• Ask follow-up questions about specific symptoms
• Assess how ADHD impacts multiple areas of your life
• Discuss treatment options, including both medication and non-medication approaches
• Explain potential side effects and what to monitor
• Answer your questions about treatment

Important: Legitimate providers won’t guarantee a prescription before your evaluation. The goal is an accurate diagnosis and appropriate treatment plan—which might include therapy, coaching, lifestyle changes, or medication (or a combination).

Safety Screening for Strattera

If your provider recommends Strattera, they’ll screen for contraindications:

• Narrow-angle glaucoma (an absolute contraindication)
• Recent MAOI use (must wait 14 days after stopping MAOIs)
• Severe cardiovascular disease (requires careful risk assessment)
• Liver problems (Strattera is metabolized by the liver)
• History of suicidal thoughts (Strattera carries an FDA warning about increased suicidal ideation in children and adolescents)

Your provider will also check your blood pressure and heart rate baseline, as Strattera can affect these. While this is typically done in-person, telehealth providers may coordinate with local labs or pharmacies for baseline measurements if needed.

Who Can Prescribe ADHD Medications Via Telehealth?

Understanding provider credentials helps you know what to expect from your telehealth consultation.

Physicians (MD/DO)

In all states, licensed physicians—including psychiatrists, primary care doctors, and other specialists—can prescribe both stimulant and non-stimulant ADHD medications via telehealth, provided they’re licensed in your state and registered with the DEA for controlled substances (if prescribing stimulants).

Nurse Practitioners (NPs) and Physician Assistants (PAs)

The prescribing authority for NPs and PAs varies significantly by state:

Full Practice Authority States (like New York, Illinois, New Hampshire):Advanced practice registered nurses (APRNs) can independently evaluate, diagnose, and prescribe ADHD medications—including both stimulants and non-stimulants—without physician oversight after meeting experience requirements.

Collaborative Practice States (like California, Florida, Pennsylvania):NPs and PAs must work under a collaborative agreement with a physician. They can still prescribe ADHD medications, but within the scope of their agreement and state regulations.

Restricted States for Controlled Substances:

• Texas: NPs and PAs cannot prescribe Schedule II stimulants in regular outpatient settings—only in hospitals or hospice care. However, they can prescribe non-stimulant medications like Strattera in collaboration with a physician.
• Georgia: State law prohibits NPs from prescribing Schedule II controlled substances entirely, even under physician supervision. Again, non-stimulants are fully accessible through NP care.

The key point: For non-stimulant ADHD medications, NPs and PAs in all states can prescribe under at least a collaborative practice model. When working with a telehealth platform like Klarity Health, you’ll be matched with appropriately credentialed providers based on your state and treatment needs.

Prescription Monitoring Programs and Safety Measures

Even though Strattera isn’t a controlled substance, expect your provider to take safety seriously.

PDMP Checks

Prescription Drug Monitoring Programs (PDMPs) are state-run databases that track controlled substance prescriptions. While non-stimulants like Strattera aren’t included in these databases, many providers still review your PDMP history as part of comprehensive care.

Why? To identify:

• Current or past stimulant ADHD medications
• Other controlled substances that might interact with ADHD treatment
• Potential patterns suggesting substance use concerns
• Medications prescribed by other providers that you might have forgotten to mention

State requirements for PDMP checks vary widely:

• Florida requires checking before every controlled substance prescription
• California mandates checks at least every four months for ongoing controlled therapy
• New Hampshire requires a check before each controlled prescription
• Georgia requires checking the first time prescribing a controlled substance, then every 90 days

For non-controlled medications, PDMP checks aren’t legally required but represent good clinical practice.

Ongoing Monitoring

Responsible telehealth ADHD care includes regular follow-ups:

First month: You’ll typically have a check-in 2-4 weeks after starting Strattera to assess:

• Early side effects (nausea, decreased appetite, mood changes)
• Medication adherence
• Any questions or concerns

Ongoing care: Monthly or quarterly appointments (depending on stability) to monitor:

• Symptom improvement
• Blood pressure and heart rate (you may be asked to check these at home or a local pharmacy)
• Liver function (baseline and periodic blood tests may be recommended)
• Overall functioning at work, school, or home
• Need for dose adjustments

Unlike stimulant medications that require monthly prescriptions with no refills (due to DEA regulations), Strattera can be prescribed with refills—often up to 90-day supplies—making ongoing management more convenient.

Advantages of Telehealth for ADHD Treatment

Understanding the benefits can help you decide if telehealth is right for you.

Accessibility and Convenience

Eliminates geographical barriers: If you live in a rural area with few mental health providers, telehealth opens access to specialists who can diagnose and treat ADHD.

Flexible scheduling: Many telehealth platforms offer evening and weekend appointments, making it easier to fit care into busy work or school schedules—something especially valuable for adults managing ADHD.

Reduced wait times: Traditional psychiatry often involves waiting weeks or months for an initial appointment. Telehealth services may offer appointments within days.

Reduced Stigma

For some people, seeking mental health treatment in person feels daunting. Telehealth provides privacy and discretion—you can attend your appointment from home without worrying about running into someone in a waiting room.

Continuity of Care

If you move frequently (students, military families, professionals with relocating jobs), finding and re-establishing care is challenging. While you’ll need a provider licensed in your new state, telehealth makes transitions smoother than starting over with in-person providers each time.

Cost Considerations

Telehealth appointments are often more affordable than in-person visits:

• Many platforms offer transparent, upfront pricing
• Insurance coverage for telehealth has expanded significantly (most plans now cover mental health telehealth at the same rate as in-person)
• No transportation costs or time off work for travel

At Klarity Health, we accept both insurance and cash pay options, with clear pricing so you know what to expect. Our providers maintain availability that often exceeds traditional practices, helping you get care when you need it.

Choosing a Reputable Telehealth ADHD Provider

The ADHD telehealth space has grown rapidly—and with that growth comes variation in quality. Here’s how to identify trustworthy care.

Red Flags to Avoid

Guaranteed prescriptions: Legitimate providers never promise a prescription before evaluating you. If a service guarantees medication, that’s a major warning sign.

No video requirement: Audio-only consultations don’t meet the standard of care for ADHD diagnosis. Reputable providers require secure video visits.

Minimal evaluation: A 5-minute questionnaire shouldn’t lead directly to a prescription. Proper ADHD evaluation takes time—typically 45-60 minutes initially.

No licensed provider contact: You should know who your provider is, their credentials, and have the ability to contact them with questions.

Pressure for stimulants only: If a provider seems dismissive of non-stimulant options or doesn’t discuss alternatives, that’s concerning.

What to Look For

Board-certified or licensed providers: Verify your provider is a licensed physician, psychiatrist, psychiatric nurse practitioner, or physician assistant properly credentialed in your state.

Comprehensive evaluations: Look for services that use validated ADHD screening tools and require thorough medical history.

Treatment variety: Quality ADHD care includes discussion of both medication and non-medication approaches (therapy, coaching, lifestyle modifications).

Clear communication: Providers should explain diagnosis, treatment options, risks, benefits, and alternatives in understandable language.

Follow-up protocols: Reputable services include structured follow-up care, not just one-time prescriptions.

Transparent pricing and insurance: You should know costs upfront and have clarity about insurance acceptance.

Privacy and security: HIPAA-compliant platforms with secure video technology protect your health information.

Why Klarity Health Stands Out

At Klarity Health, we’ve built our ADHD telehealth service with these principles in mind:

• Experienced providers: Our network includes board-certified psychiatrists and psychiatric nurse practitioners who specialize in ADHD
• Thorough evaluations: We use evidence-based diagnostic criteria and validated screening tools
• Personalized treatment plans: We discuss all options—stimulants, non-stimulants, therapy, and lifestyle approaches—to find what works best for you
• Transparent pricing: Clear costs upfront, whether you’re using insurance or paying cash
• Strong availability: Get appointments quickly with providers who maintain accessible schedules
• Ongoing support: Regular follow-ups ensure your treatment is working and adjust as needed

Understanding Strattera: What to Expect

If your provider prescribes Strattera, knowing what to expect helps you succeed with treatment.

How Strattera Works

Unlike stimulants that increase dopamine levels rapidly, Strattera works gradually by blocking the reuptake of norepinephrine. This neurotransmitter plays a key role in attention, focus, and impulse control.

Timeline for effects:

• Week 1-2: Minimal symptom improvement; possible initial side effects
• Week 4-6: Noticeable improvement in attention and focus for many patients
• Week 8-12: Full therapeutic effects typically achieved

This gradual onset means patience is important—Strattera isn’t a quick fix, but for many people, it provides steady, all-day symptom management without the ups and downs that can occur with stimulants.

Common Side Effects

Most side effects are mild and often improve after the first few weeks:

Common (typically temporary):

• Decreased appetite
• Nausea or upset stomach
• Dry mouth
• Fatigue or drowsiness (or sometimes insomnia)
• Dizziness

Less common but important:

• Increased blood pressure or heart rate (your provider will monitor)
• Mood changes or irritability
• Sexual side effects

Serious (rare):

• Liver problems (watch for yellowing of skin/eyes, dark urine, upper right abdominal pain)
• Severe allergic reactions
• Increased suicidal thoughts (particularly in children and adolescents—report immediately)

Your telehealth provider should educate you about what to monitor and when to reach out with concerns.

Practical Tips for Success

Take consistently: Strattera works best when taken daily at the same time, even on weekends or days off.

Don’t skip doses: Missing doses can set back your progress since the medication requires steady levels.

Communicate openly: Tell your provider about any side effects, even if they seem minor. Sometimes simple adjustments (taking with food, changing timing, adjusting dose) make a big difference.

Be patient: Remember the 4-6 week timeline. Many people feel discouraged in the first few weeks before benefits emerge.

Complement with strategies: Medication works best alongside organizational skills, routines, exercise, adequate sleep, and potentially therapy or coaching.

What Happens If Regulations Change?

Given the evolving regulatory landscape, it’s natural to wonder about the future of telehealth ADHD care.

Current Outlook

For non-stimulant medications, the outlook is stable. Federal law has never restricted telehealth prescribing of non-controlled substances, and no proposed regulations would change that. As long as providers follow standard medical practices and state licensing requirements, Strattera and similar medications will remain accessible via telehealth.

For stimulant medications, uncertainty exists beyond December 31, 2025, when the current DEA extension expires. Possible scenarios include:

1. Another extension (most likely): The DEA is expected to finalize a fourth extension for 2026, maintaining current flexibilities.

2. New permanent framework: The DEA has proposed a ‘Special Registration’ pathway that would allow controlled substance prescribing via telehealth under specific safeguards. This isn’t finalized but could provide long-term clarity.

3. Return to Ryan Haight requirements: If extensions end without replacement, the original in-person examination requirement could resume for controlled substances. This would affect stimulants but not non-stimulants.

What This Means for You

If you’re currently receiving telehealth ADHD care or considering it:

If prescribed non-stimulants: Your access should remain stable regardless of regulatory changes. Federal law doesn’t restrict these medications, and state laws largely accommodate telehealth prescribing.

If prescribed stimulants: Stay informed through your telehealth provider, who will communicate any necessary changes well in advance. If in-person requirements return, you’d have options:

• Transition to a local in-person provider for initial exam, then continue telehealth for follow-ups
• Switch to a non-stimulant medication that remains telehealth-accessible
• Coordinate ‘hybrid care’ where your telehealth provider works with a local doctor who can see you in person

Proactive steps:

• Ask your provider about their contingency plans for potential regulatory changes
• Keep your contact information current so you receive updates
• Attend all follow-up appointments and maintain good communication
• Consider establishing a relationship with a local provider as a backup if you rely on stimulants

The telehealth industry, medical associations, and patient advocacy groups are actively working to preserve and expand telehealth access. The trajectory has been toward greater flexibility, not restriction—especially for mental health conditions like ADHD.

Frequently Asked Questions

Q: Can I get an ADHD diagnosis via telehealth if I’ve never been diagnosed before?

A: Yes. Licensed providers can diagnose ADHD through comprehensive telehealth evaluations using the same DSM-5 criteria as in-person assessments. Your provider will review your symptom history, administer screening tools, and may request collateral information to ensure accurate diagnosis.

Q: Will my insurance cover telehealth ADHD treatment?

A: Most insurance plans now cover telehealth mental health services at the same rate as in-person care, particularly after COVID-era policy changes became permanent. Check with your specific plan. Klarity Health works with major insurance providers and can verify your coverage before your appointment.

Q: How long does it take to get started with telehealth ADHD treatment?

A: Timeline varies by provider, but many telehealth platforms offer appointments within days rather than the weeks or months typical of traditional psychiatry. After your initial evaluation, if medication is prescribed, you can usually pick it up from your pharmacy within 24-48 hours.

Q: Can I use telehealth if I’m already being treated for ADHD by another provider?

A: Yes, though you should inform both providers to ensure coordinated care. If you’re switching from in-person to telehealth care, your new provider will likely request records from your previous provider to understand your treatment history.

Q: What if Strattera doesn’t work for me?

A: Your provider will reassess and discuss alternatives, which might include:

• Adjusting the Strattera dose (therapeutic range varies)
• Trying a different non-stimulant medication
• Considering stimulant medications if appropriate for your situation
• Adding behavioral therapy or coaching
• Investigating whether another condition might be contributing to symptoms

Q: Is telehealth ADHD treatment safe?

A: When provided by licensed, qualified professionals following evidence-based practices, telehealth ADHD treatment is safe and effective. Research shows outcomes comparable to in-person care for ADHD evaluation and management. The key is choosing reputable providers who conduct thorough evaluations and provide ongoing monitoring.

Q: Can children and adolescents receive ADHD treatment via telehealth?

A: Many telehealth platforms treat adolescents and some treat children, though age cutoffs vary. For younger children (under 12), in-person evaluation is often recommended due to the complexity of assessment. Parent or guardian participation is typically required for minors. Check with specific providers about their age policies.

Taking the Next Step

If you’re struggling with ADHD symptoms—difficulty concentrating at work, trouble completing tasks, disorganization affecting your relationships, or impulsive decisions causing problems—effective treatment is more accessible than ever.

Telehealth has transformed ADHD care, removing barriers that once prevented millions from getting help. Whether you’re newly considering treatment or looking for a more convenient way to manage your existing care, non-stimulant medications like Strattera offer a safe, accessible option through telehealth platforms.

Getting Started With Klarity Health

At Klarity Health, we’ve made ADHD care straightforward:

1. Schedule your evaluation: Book an appointment with a licensed provider in your state—often available within days
2. Complete your assessment: Meet with your provider via secure video for a comprehensive ADHD evaluation
3. Receive your personalized treatment plan: If appropriate, your provider will prescribe medication and discuss additional strategies for managing ADHD
4. Access ongoing support: Regular follow-ups ensure your treatment is working and can be adjusted as needed

We understand that managing ADHD is challenging enough without navigating complicated healthcare systems. Our providers offer the expertise you need with the convenience and accessibility you deserve—transparent pricing, insurance and cash pay options, and strong provider availability to get you care when you need it.

Ready to take control of your ADHD? The first step is reaching out. Effective treatment can improve every aspect of your life—from work performance to relationships to your overall sense of well-being.

Citations and References

1. Drug Enforcement Administration (DEA). ‘Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications.’ Federal Register, November 2024. Available at: https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final

2. McDermott Will & Emery. ‘DEA Signals Extension of Telemedicine Flexibilities for Controlled Substance Prescribing for 2026.’ December 2025. Available at: https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/

3. Sheppard Mullin Richter & Hampton LLP. ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions.’ National Law Review, August 15, 2025. Available at: https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/

4. RxAgent Blog. ‘The Telehealth Compliance Trap: What Prescribers Must Know About Upcoming DEA Changes.’ October 2025. Available at: https://www.rxagent.co/blog/telehealth-compliance-trap

5. Medical News Today. ‘Is Strattera a Controlled Substance?’ Medically reviewed, January 14, 2025. Available at: https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance

Disclaimer: This article is for informational purposes only and does not constitute medical advice. ADHD diagnosis and treatment should be managed by qualified healthcare professionals. Regulations and laws are current as of December 17, 2025, and may change. Always verify current requirements with your healthcare provider and state medical board.

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment